Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q3 2016 · 10-Q
Revenue$3.13M$3.13M−30.2% vs Q3 2015 Net Income-$1.75M-$1.75MN/M vs Q3 2015 EPS Diluted-$0.04-$0.04N/M vs Q3 2015 Gross Profit$349,968+8.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Operating Cash Flowderived$866,836−25.8% Free Cash Flowderived$846,699−27.5% Margins · derivedGross margin11.2%+4.0 pt vs Q3 2015
Operating margin-49.5%−120.8 pt vs Q3 2015
Net margin-56.0%−121.4 pt vs Q3 2015
ended Sep 30, 2016 · filed Nov 14, 2016 · 45 d after period end